The DOI matches its Crossref record; 457 of the 457 references it cites were found in a registry or an index.
Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential
Open accessAbstract
Synaptic abnormalities are a cardinal feature of Alzheimer’s disease (AD) that are known to arise as the disease progresses. A growing body of evidence suggests that pathological alterations to neuronal circuits and synapses may provide a mechanistic link between amyloid β (Aβ) and tau pathology and thus may serve as an obligatory relay of the cognitive impairment in AD. Brain-derived neurotrophic factors (BDNFs) play an important role in maintaining synaptic plasticity in learning and memory. Considering AD as a synaptic disorder, BDNF has attracted increasing attention as a potential diagnostic biomarker and a therapeutical molecule for AD. Although depletion of BDNF has been linked with Aβ accumulation, tau phosphorylation, neuroinflammation and neuronal apoptosis, the exact mechanisms underlying the effect of impaired BDNF signaling on AD are still unknown. Here, we present an overview of how BDNF genomic structure is connected to factors that regulate BDNF signaling. We then discuss the role of BDNF in AD and the potential of BDNF-targeting therapeutics for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“BDNF is a major regulator of neuronal survival and synaptic plasticity and has been linked to synaptic dysfunction in AD (Gao et al., 2022; Lu et al., 2014), whereas IL1B is a major mediator of AD-associated neuroinflammatory signaling (Lopez-Rodriguez et al., 2021).”
From Isogenic human stem cell models reveal mutation-dependent protective mechanisms of APOE3 Christchurch (2026) · cites this paper as Gao et al., 2022
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“Different hypotheses have been proposed to explain the pathologic process of AD, including the cholinergic hypothesis [17], the tau hypothesis [18, 19], the glutamate dysfunction hypothesis [20], the amyloid cascade hypothesis [21, 22], the inflammatory hypothesis [23], and the mitochondrial cascade hypothesis [24].”
BackgroundThe cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Molecular characterization of a peripheral receptor for cannabinoids
Munro, S., Thomas, K. L., & Abu-Shaar, M. (1993) · Nature · doi:10.1038/365061a0 · Cited by 5,092
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619
Meta-Analysis of 74,046 Individuals Identifies 11 New Susceptibility Loci for Alzheimer’s Disease
(EADI), E. A. D. I., Lambert, J.-C., (GERAD), G. A. E. R. I. A. D., Alzheimer's Disease Genetic Consortium (ADGC), (CHARGE), C. F. H. A. A. R. I. G. E., Ibrahim-Verbaas, C. A., Harold, D., Naj, A. C., Sims, R., Bellenguez, C., et al. (2013) · Nature Genetics · doi:10.1038/ng.2802 · Cited by 4,336 · cited 1×
“Genomewide association studies of AD have similarly shown that the BDNF Val66Met is not a risk factor for AD [170].”
BackgroundRequirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 1×
“Estradiol (E2) and BDNF have also been shown to help regulate many of the same biological functions, including modulating the activity of NMDARs (especially the NR2B subunit), promoting neurogenesis in the dentate gyrus, and facilitating the formation of memories [276, 277].”
Background
Research works printed but not linked: 11
- Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Zentralbl Nervenh Psych. 1907;18:177–9.
- Cavazzoni P. FDA’s decision to approve new treatment for Alzheimer’s disease. U.S. Food and Drug Administration; 2021.
- Weinstein G, Beiser AS, Choi SH, Preis SR, Chen TC, Vorgas D, et al. Serum Brain-derived neurotrophic factor and the risk for dementia the framingham heart study. JAMA Neurol. 2014;71(1):55–61. · DOI · Paper page
- Franzmeier N, Ren J, Damm A, Monté-Rubio G, Boada M, Ruiz A, et al. The BDNFVal66Met SNP modulates the association between beta-amyloid and hippocampal disconnection in Alzheimer’s disease. Mol Psychiatry. 2021;26(2):614–28. · DOI
- Jiao SS, Shen LL, Zhu C, Bu XL, Liu YH, Liu CH, et al. Brain-derived neurotrophic factor protects against tau-related neurodegeneration of Alzheimer’s disease. Transl Psychiatry. 2016;6(10):e907. · DOI · Paper page
- Lipsky RH, Ke Xu, Zhu D, Kelly C, Terhakopian A, Novelli A, et al. Nuclear factor kB is a critical determinant in N-methyl-d-aspartate receptor-mediated neuroprotection. J Neurochem. 2001;78:254–64. · DOI · Paper page
- Liu D, Zhang M, Jiang X, Lei H, Li J, Wang X. Protective effects and the mechanisms of donepezil and galantamine on neuronal injury induced by glucose deprivation/reoxygenation. Acta Pharm Sin. 2017;12:928–35.
- Khundakar A, Zetterstrom T, editors. Differential expression of BDNF exons in rat brain after systemic administration of paroxetine and tranylcypromine. Nature Publishing Group; 2002.
- Orgeta V, Tabet N, Nilforooshan R, Howard R, Leoutsakos J-M. Efficacy of antidepressants for depression in Alzheimer’s disease: systematic review and meta-analysis. J Alzheimers Dis. 2017;58(3):725–33. · DOI · Paper page
- Pakulska MM, Elliott Donaghue I, Obermeyer JM, Tuladhar A, McLaughlin CK, Shendruk TN, et al. Encapsulation-free controlled release: electrostatic adsorption eliminates the need for protein encapsulation in PLGA nanoparticles. Sci Adv. 2016;2(5):e1600519. · DOI
- Günther MI, Weidner N, Müller R, Blesch A. Cell-seeded alginate hydrogel scaffolds promote directed linear axonal regeneration in the injured rat spinal cord. Acta Biomater. 2015;27:140–50. · DOI
Cited by
Integrated multimodal cell atlas of Alzheimer’s disease
Gabitto, M. I., Travaglini, K. J., Rachleff, V. M., Kaplan, E. S., Long, B., Ariza, J., Ding, Y., Mahoney, J. T., Dee, N., Goldy, J., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01774-5 · Cited by 397
“Finally, it is possible that Sst neuron loss could also disrupt trophic support of connected neurons 94 , ultimately leading to the loss of long-range corticocortical connectivity that would be expected to affect cognitive function.”
Apoptosis in Alzheimer’s disease: Insight into the signaling pathways and therapeutic avenues
Kumari, S., Dhapola, R., & Reddy, D. H. (2023) · Apoptosis · doi:10.1007/s10495-023-01848-y · Cited by 324
Akyuz, E., Arulsamy, A., Aslan, F. S., Sarisözen, B., Guney, B., Hekimoglu, A., Yilmaz, B. N., Retinasamy, T., & Shaikh, M. F. (2025) · Molecular Neurobiology · doi:10.1007/s12035-024-04333-y · Cited by 69
Ali, M., Timsina, J., Western, D., Liu, M., Beric, A., Budde, J., Do, A., Heo, G., Wang, L., Gentsch, J., et al. (2025) · Neuron · doi:10.1016/j.neuron.2025.02.014 · Cited by 61
Gupta, A. K., Gupta, S., Mehan, S., Khan, Z., Das Gupta, G., & Narula, A. S. (2025) · Molecular Neurobiology · doi:10.1007/s12035-025-05001-5 · Cited by 59
Metadata
- Authors
- Gao, L., Zhang, Y., Sterling, K., & Song, W.
- Affiliations
- University of British Columbia (CA)
- Capital Medical University (CN)
- Corresponding author
- Song, Weihong
- Venue
- Translational Neurodegeneration
- Published
- 2022-01-28
- Volume
- 11
- Issue
- 1
- Pages
- 4-4
- ISSN
- 2047-9158 (ISSN-L)
- PMC
- PMC8796548
- OpenAlex
- W4210324338
- Cited by
- 606
- References
- 457
- Citations by year
- 2026: 137 · 2025: 174 · 2024: 167 · 2023: 103 · 2022: 25
- FWCI
- 16.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Translational Neurodegeneration (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- cIRcle (University of British Columbia) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Open Collections
- Funders
- Natural Science Foundation of Shanghai (81903824)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- brain-derived neurotrophic factor, Alzheimer's disease, synaptic dysfunction, amyloid-beta, tau pathology, BDNF signaling, neuroinflammation, neuronal apoptosis, diagnostic biomarkers, synaptic plasticity
- MeSH terms
- Alzheimer Disease, Pharmaceutical Preparations, Humans, Neurons, Amyloid beta-Peptides, Brain-Derived Neurotrophic Factor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential. https://app.cochat.ai/papers/10.1186/s40035-022-00279-0
- The paper
- Gao, L., Zhang, Y., Sterling, K., & Song, W. (2022). Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential. Translational Neurodegeneration. https://doi.org/10.1186/s40035-022-00279-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.